Coltene saw no growth in patent filings in April and highest growth of 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Coltene’s patent filings and grants. Buy the databook here.
Coltene has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 50% of grants. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Coltene is filings its patents. Among the top granted patent authorities, Coltene has 50% of its grants in European Patent Office(EPO) and 50% in United States(US).
Dentsply Sirona could be the strongest competitor for Coltene
In terms of grant share, Coltene stands in eighth position among its competitors. Coltene and Dentsply Sirona secured the top positions according to recent patent publication data.
Patents related to nanomedicine lead Coltene's portfolio
Coltene has the highest number of patents in nanomedicine. For nanomedicine no patents were filed and 100% of patents were granted in Q2 2024.
Aerospace materials & structural components related patents lead Coltene portfolio followed by dental devices
Coltene has highest number of patents in aerospace materials & structural components followed by dental devices.
For comprehensive analysis of Coltene's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.